Eleven Biotherapeutics (EBIO – Snapshot Report) suffered a huge setback with its lead pipeline candidate failing in a late-stage study. Meanwhile, companies like bluebird (BLUE – Snapshot Report), Agios (AGIO – Snapshot Report) and Acceleron (XLRN – Snapshot Report) all got encouraging news on the regulatory front. Achillion (ACHN – Snapshot Report) struck a collaboration agreement with Johnson & Johnson […]
Biotech stocks are among the market’s riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials, and three have high-profile big-cap partners.Source: Flickr user Carlos Gracia1. Proven performerInsys Therapeutics is already rewarding shareholders with rapid sales growth and profitability, but […]
View gallery.The graphs below were produced by Capital Market Labs.A critical factor in assessing pharmaceutical and biotech companies is the quality of their drug pipelines. This is especially true as investors begin to look at the smaller companies in the space; the smaller the company, the more an investment is simply a bet on that particular pipeline.So, let’s take a look […]
